嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
作者信息
Levine Bruce L, Pasquini Marcelo C, Connolly John E, Porter David L, Gustafson Michael P, Boelens Jaap J, Horwitz Edwin M, Grupp Stephan A, Maus Marcela V, Locke Frederick L, Ciceri Fabio, Ruggeri Annalisa, Snowden John, Heslop Helen E, Mackall Crystal L, June Carl H, Sureda Anna M, Perales Miguel-Angel
机构信息
Center for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
出版信息
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
Abstract
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
摘要
嵌合抗原受体T细胞（CAR-T）疗法后T细胞恶性肿瘤的报告应予以调查，但随访研究的现有数据表明，与其他癌症治疗方法相比，其风险较低。
相似文献
1
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
2
CAR-T cell therapy for patients with hematological malignancies. A systematic review.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤。系统评价。
Eur J Haematol. 2022 Dec;109(6):601-618. doi: 10.1111/ejh.13851. Epub 2022 Sep 18.
3
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.优化血液系统恶性肿瘤嵌合抗原受体 T 细胞治疗的策略：中国经验。
Haematologica. 2023 Aug 1;108(8):2011-2028. doi: 10.3324/haematol.2022.282316.
4
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.嵌合抗原受体 T 细胞治疗后免疫效应细胞相关神经毒性综合征的临床表现、危险因素和结局：系统评价。
Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11.
5
State of the art in CAR T cell therapy for CD19+ B cell malignancies.嵌合抗原受体 T 细胞疗法治疗 CD19+ B 细胞恶性肿瘤的最新进展。
J Clin Invest. 2020 Apr 1;130(4):1586-1594. doi: 10.1172/JCI129208.
6
Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.通用嵌合抗原受体T细胞疗法——细胞疗法的未来：一项提供临床证据的综述
Cancer Treat Res Commun. 2022;33:100638. doi: 10.1016/j.ctarc.2022.100638. Epub 2022 Sep 22.
7
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.深入了解下一代 CAR 疗法：设计 CAR T 细胞以改善临床结果。
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI142030.
8
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.嵌合抗原受体T细胞免疫疗法的临床前开发：设计对疗效和安全性的影响
Best Pract Res Clin Haematol. 2018 Jun;31(2):117-125. doi: 10.1016/j.beha.2018.04.002. Epub 2018 Apr 21.
9
Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.CD19特异性嵌合抗原受体T细胞疗法后复发或难治性B细胞淋巴瘤患者带状疱疹的发病率及预防
Leuk Lymphoma. 2022 Apr;63(4):1001-1004. doi: 10.1080/10428194.2021.2010062. Epub 2021 Nov 28.
10
Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.血液系统恶性肿瘤嵌合抗原受体 T 细胞治疗的研究趋势和活跃研究领域的文献计量学分析。
Int J Clin Pharm. 2024 Feb;46(1):186-194. doi: 10.1007/s11096-023-01670-1. Epub 2023 Dec 12.
引用本文的文献
1
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.造血细胞移植和嵌合抗原受体T细胞疗法治疗血液系统疾病、实体瘤及免疫紊乱的适应证：2025年欧洲血液与骨髓移植学会实践建议
Bone Marrow Transplant. 2025 Sep 9. doi: 10.1038/s41409-025-02701-3.
2
Targeting the roots of myeloid malignancies with T cell receptors.利用T细胞受体靶向髓系恶性肿瘤的根源。
Nat Rev Cancer. 2025 Aug 21. doi: 10.1038/s41568-025-00857-0.
3
Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.揭示CAR阴性T细胞的影响：提高CAR-T疗法的疗效并确保安全性。
J Transl Med. 2025 Aug 19;23(1):942. doi: 10.1186/s12967-025-06899-0.
4
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.与治疗干预相关的非典型淋巴样增殖：2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.
5
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.在CAR-T治疗后被诊断为T细胞淋巴瘤的克隆性扩增的淋巴结T细胞群体。
Nat Commun. 2025 Aug 12;16(1):7462. doi: 10.1038/s41467-025-62709-7.
6
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.工程化过继性细胞免疫疗法中生物医学虚拟孪生体的设计规范。
NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.
7
Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.特发性炎性肌病中新兴的B细胞和浆细胞靶向免疫疗法。
Front Immunol. 2025 Jul 17;16:1581323. doi: 10.3389/fimmu.2025.1581323. eCollection 2025.
8
Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.晚期透明细胞肾细胞癌免疫治疗和靶向治疗的进展：当前策略与未来方向
Front Immunol. 2025 Jul 3;16:1582887. doi: 10.3389/fimmu.2025.1582887. eCollection 2025.
9
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
10
In vitro HIV DNA integration in STAT3 drives T cell persistence-A model of HIV-associated T cell lymphoma.体外HIV DNA整合入STAT3驱动T细胞持续存在——一种HIV相关T细胞淋巴瘤的模型
PLoS Pathog. 2025 Jul 8;21(7):e1013087. doi: 10.1371/journal.ppat.1013087. eCollection 2025 Jul.
本文引用的文献
1
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease.基因治疗镰状细胞病后造血干细胞的克隆选择。
Nat Med. 2023 Dec;29(12):3175-3183. doi: 10.1038/s41591-023-02636-6. Epub 2023 Nov 16.
2
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.国家基因载体生物库中的复制型逆转录病毒检测（RCR）：60 项临床试验的 1595 份治疗后外周血样本中未发现 RCR。
Mol Ther. 2023 Mar 1;31(3):801-809. doi: 10.1016/j.ymthe.2022.12.006. Epub 2022 Dec 14.
3
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.CD19嵌合抗原受体T细胞疗法后后续恶性肿瘤发生率低。
Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093.
4
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.输注前因素对 CD19 CAR T 细胞回输后免疫表型复发的影响。
Blood Adv. 2023 Feb 28;7(4):575-585. doi: 10.1182/bloodadvances.2022007423.
5
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.经基因修饰的肠内分泌细胞治疗后的患者发生后续恶性肿瘤的长期随访。
Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728.
6
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.猪源 Bac 修饰的 CD19 嵌合抗原受体 T 细胞输注后产品相关淋巴瘤的研究。
Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858.
7
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.双向增加 B 细胞淋巴瘤和 T 细胞淋巴瘤的风险。
Blood. 2021 Sep 2;138(9):785-789. doi: 10.1182/blood.2020010497.
8
T-cell lymphoma secondary to checkpoint inhibitor therapy.继发于检查点抑制剂治疗的 T 细胞淋巴瘤。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000104.
9
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.霍奇金淋巴瘤治疗后 40 年内的二次癌症风险。
N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.
10
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.逆转录病毒插入激活 Janus 激酶 1 诱导的成熟 T 细胞淋巴肿瘤发生。
Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.
Zotero 插件